NCT04950075

Study of INBRX-109 in Conventional Chondrosarcoma

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 206 (actual)
• Sponsor: Inhibrx Biosciences, Inc · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Detailed description

This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Conditions

• Conventional Chondrosarcoma

Interventions

Type	Name	Description
DRUG	INBRX-109	Tetravalent DR5 Agonist Antibody
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-09-23
• Primary completion: 2025-09-30
• Completion: 2026-12-01
• First posted: 2021-07-06
• Last updated: 2026-01-09

Locations

68 sites across 9 countries: United States, Australia, France, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study